

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Vatera Healthcare Partners LLC</u> <hr/> (Last) (First) (Middle) C/O VATERA HOLDINGS LLC 499 PARK AVENUE, 23RD FLOOR <hr/> (Street) NEW YORK NY 10022 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/03/2017	3. Issuer Name and Ticker or Trading Symbol <u>MELINTA THERAPEUTICS, INC. /NEW/ [ MLNT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,729,459	D <sup>(1)</sup>	
Common Stock	6,729,459	I	See Footnote <sup>(1)</sup>
Common Stock	6,729,459	I	See Footnote <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>Vatera Healthcare Partners LLC</u> <hr/> (Last) (First) (Middle) C/O VATERA HOLDINGS LLC 499 PARK AVENUE, 23RD FLOOR <hr/> (Street) NEW YORK NY 10022 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>VATERA HOLDINGS LLC</u> <hr/> (Last) (First) (Middle) 499 PARK AVENUE, 23RD FLOOR <hr/> (Street) NEW YORK NY 10022 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person\*

[Ferro Kevin](#)

(Last) (First) (Middle)

[C/O VATERA HOLDINGS LLC](#)  
[499 PARK AVENUE, 23RD FLOOR](#)

(Street)

[NEW YORK](#) [NY](#) [10022](#)

(City) (State) (Zip)

**Explanation of Responses:**

1. See Exhibit 99.1.

**Remarks:**

Exhibit List: [Exhibit 99.1 - Explanation of Responses](#) [Exhibit 99.2 - Joint Filers' Signatures](#)

[VATERA HEALTHCARE](#)  
[PARTNERS LLC, By: Vatera](#)  
[Holdings LLC, its Manager,](#)  
[By: /s/ Kevin Ferro, Title: 11/13/2017](#)  
[Chief Executive Officer, Chief](#)  
[Investment Officer and](#)  
[Managing Member](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## Explanation of Responses

- (1) Vatera Healthcare Partners LLC directly owns 6,729,459 shares of common stock of the Issuer (the "Shares") received upon consummation of the merger (the "Merger") of a subsidiary of the Issuer into a company now known as Melinta Subsidiary Corp. on November 3, 2017. Vatera Holdings LLC is the manager of Vatera Healthcare Partners LLC and Kevin Ferro serves as the Chief Executive Officer, Chief Investment Officer and Managing Member of Vatera Holdings LLC. Vatera Healthcare Partners LLC, Vatera Holdings LLC and Mr. Ferro are Reporting Persons on this Form 3. Pursuant to Rule 13d-3 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), Vatera Holdings LLC and Mr. Ferro may be deemed to beneficially own the Shares owned directly by Vatera Healthcare Partners LLC. Each of Vatera Holdings LLC and Mr. Ferro disclaims beneficial ownership of any Shares owned by Vatera Healthcare Partners LLC, except to the extent of its or his pecuniary interest therein. Mr. Ferro serves on the Board of Directors of the Issuer (the "Board"), together with Cecilia Gonzalo, a managing director of Vatera Holdings LLC, and Thomas P. Koestler, Ph.D., an executive director of Vatera Holdings LLC. Solely for purposes of Section 16 of the Exchange Act, Vatera Healthcare Partners LLC and Vatera Holdings LLC may be deemed to be directors-by-deputization as a result of the service of such persons on the Board. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the Board approved the acquisition of any direct or indirect pecuniary interest in any and all Shares by the Reporting Persons as a result of or in connection with the Merger.

**JOINT FILERS' SIGNATURES**

**VATERA HOLDINGS LLC**

By: /s/ Kevin Ferro  
Name: Kevin Ferro  
Title: Chief Executive Officer, Chief Investment  
Officer and Managing Member

/s/ Kevin Ferro  
**Kevin Ferro**